Core G: Neuroimaging Core

摘要：神经成像核心 神经影像学提供了一种独特的非侵入性能力，以探索结构，功能和代谢 从细胞到整个生物体。堪萨斯大学阿尔茨海默病中心（KU ADC）神经影像学 核心提供了一个广泛的综合平移成像方法，结合动物和人类的磁 由正电子发射断层扫描补充的共振成像能力。这些方法 特别适合KU ADC能量代谢主题，因为Neuroimaging Core带来了世界一流的 磁共振波谱的优势以及其他成像方法的巨大深度。这些 能力已经影响了新的调查员招聘到KU ADC，与新的教职员工， 博士后研究员和研究生将KU ADC的成像能力确定为 他们选择搬到KU的重要因素。 神经影像学核心将促进KU ADC的目标，即扩大对衰老的研究， 神经退行性疾病，如阿尔茨海默病（AD），通过提供研究者（i）神经成像 设施，专业知识和成像科学的先进教育，（ii）一批良好的- 具有成像数据的特征性认知正常（CN）和轻度认知障碍（MCI）受试者 与临床（临床核心）和遗传数据（MGM核心）相关联，以及（iii）新方法， 研究人员在研究中利用先进的成像技术。 我们的具体目标是： 目标1.提供集成的成像环境，为AD和 老化研究Neuroimaging Core为经批准的研究者提供最先进的成像技术 支持设计、数据收集和分析的设施、教师合作者和高级科学家，以及 结果的解释和公布。神经影像学核心还提供先进的专业培训， 显像 目标二。为研究者提供神经影像学队列，并提供纵向影像学支持， 刺激AD和衰老的成像研究。神经影像学核心是表征一个样本的 每2年进行一次MRI的临床队列。该神经成像队列由CN参与者（n>100）组成 淀粉样蛋白升高，n>100淀粉样蛋白未升高）和MCI参与者（n>100）。参与者将被扫描 每2年进行一次扫描，并分析扫描结果，以提供存储在ADC数据库中的脑部和病变体积。 这些数据可供研究人员使用，以刺激新的研究和未来的拨款申请。 目标3.开发AD和衰老研究中的成像新技术。神经成像核心将 开发与KU ADC的能量代谢主题相关的新型MRI和PET成像方法。

ABSTRACT: NEUROIMAGING CORE Neuroimaging provides a unique non-invasive capability to explore the structure, function, and metabolism from cells to whole organisms. The University of Kansas Alzheimer’s Disease Center (KU ADC) Neuroimaging Core provides a broad integrated translational imaging approach that combines animal and human magnetic resonance imaging capability complemented by positron emission tomography. These approaches are especially suitable for the KU ADC energy metabolism theme since the Neuroimaging Core brings world-class strengths in magnetic resonance spectroscopy as well as great depth in other imaging approaches. These capabilities have impacted the recruitment of new investigators to the KU ADC, with new faculty members, postdoctoral fellows and graduate students identifying the imaging capability of the KU ADC as being a significant factor in their choosing to move to KU. The Neuroimaging Core will facilitate the KU ADC goal of expanding research into aging and neurodegenerative disorders such as Alzheimer’s disease (AD) by providing investigators with (i) neuroimaging facilities, professional expertise, and advanced education in imaging sciences, (ii) a cohort of well- characterized cognitively-normal (CN) and mild cognitive impairment (MCI) participants with imaging data linked to clinical (Clinical Core) and genetic data (MGM Core), and (iii) new methods that will enable investigators to exploit advanced imaging in their studies. Our specific aims are: Aim 1. Provide an integrated imaging environment with advanced support and training for AD and aging research. The Neuroimaging Core provides approved investigators with state-of-the-art imaging facilities and faculty collaborators and senior scientists who support design, data collection and analysis, and interpretation and publication of results. The Neuroimaging Core also provides specialized training in advanced imaging. Aim 2. Provide investigators with a Neuroimaging Cohort with longitudinal imaging to support and stimulate imaging research in AD and Aging. The Neuroimaging Core is characterizing a sample of the Clinical Cohort with MRI every 2 years. This Neuroimaging Cohort is comprised of CN participants (n>100 amyloid elevated, n>100 amyloid non-elevated) and MCI participants (n>100). Participants will be scanned every 2 years and scans will be analyzed to provide brain and lesion volumes stored in the ADC database. These data are available to investigators to stimulate new research and future grant applications. Aim 3. Develop novel techniques for imaging in AD and aging research. The Neuroimaging Core will develop novel MRI and PET imaging methods, related to the energy metabolism theme of the KU ADC.